TISIDB

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Golgi apparatus
Domain	PF01467 Cytidylyltransferase-like
Function	Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate but with a lower efficiency. Cannot use triazofurin monophosphate (TrMP) as substrate. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity prefers NAD(+), NADH and NaAD as substrates and degrades nicotinic acid adenine dinucleotide phosphate (NHD) less effectively. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+).

> Gene Ontology [ TOP ]
Biological Process	GO:0006520 cellular amino acid metabolic process GO:0006531 aspartate metabolic process GO:0006732 coenzyme metabolic process GO:0006733 oxidoreduction coenzyme metabolic process GO:0009066 aspartate family amino acid metabolic process GO:0009108 coenzyme biosynthetic process GO:0009165 nucleotide biosynthetic process GO:0009435 NAD biosynthetic process GO:0019355 nicotinamide nucleotide biosynthetic process from aspartate GO:0019359 nicotinamide nucleotide biosynthetic process GO:0019362 pyridine nucleotide metabolic process GO:0019363 pyridine nucleotide biosynthetic process GO:0019674 NAD metabolic process GO:0034627 'de novo' NAD biosynthetic process GO:0034628 'de novo' NAD biosynthetic process from aspartate GO:0043648 dicarboxylic acid metabolic process GO:0046496 nicotinamide nucleotide metabolic process GO:0051186 cofactor metabolic process GO:0051188 cofactor biosynthetic process GO:0072524 pyridine-containing compound metabolic process GO:0072525 pyridine-containing compound biosynthetic process GO:1901293 nucleoside phosphate biosynthetic process GO:1901605 alpha-amino acid metabolic process
Molecular Function	GO:0000309 nicotinamide-nucleotide adenylyltransferase activity GO:0004515 nicotinate-nucleotide adenylyltransferase activity GO:0016779 nucleotidyltransferase activity GO:0070566 adenylyltransferase activity
Cellular Component	GO:0005770 late endosome GO:0005802 trans-Golgi network GO:0031984 organelle subcompartment GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00760 Nicotinate and nicotinamide metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-1430728: Metabolism R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-196849: Metabolism of water-soluble vitamins and cofactors R-HSA-196807: Nicotinate metabolism

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NMNAT2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NMNAT2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NMNAT2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.024	0.928
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.381	0.432
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.325	0.457
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.528	0.171
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.4	0.747
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.688	0.644
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.187	0.742
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.285	0.735
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.092	0.918
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.553	0.587
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.539	0.684
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.682	0.0133

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NMNAT2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NMNAT2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NMNAT2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NMNAT2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NMNAT2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NMNAT2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NMNAT2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NMNAT2
Name	nicotinamide nucleotide adenylyltransferase 2
Aliases	KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location	1q25
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NMNAT2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NMNAT2